Iscar for Supplemental Care in Stage IV Lung Cancer

Phase 2

Completed

• Conditions: Lung Cancer

• Registration Number: NCT00079794
• Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Brief Summary

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Detailed Description

See Brief Summary

Study Timeline

• Study Start: 2001-09
• Primary Completion: 2004-02
• Study Completion: 2004-02
• Study First Submitted: 2004-03-15
• Study First Submitted QC: 2004-03-15
• Study First Posted: 2004-03-16
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-23
• Last Update Posted: 2008-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria:

• Known allergy to Viscum Album L.
• Concomitant use of other mistletoe products
• Concomitant use of mushroom glucan and proteoglycan extracts
• Concomitant use of thymus extract products
• Inability to self-report quality of life utilizing assessment tools
• Ongoing steroid or ACTH therapy
• Co-morbid immunocompromised state
• Pregnancy
• Participation in other clinical trials

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States